CRT 2026

LATE-BREAKING CLINICAL TRIALS | CORONARY III

Moderator(s)

• 

  George Dangas, MD, MACC, MSCAI

  PROFESSOR OF CARDIOLOGY
  The Mount Sinai Hospital
  New York, New York, United States

  Disclosure(s): No financial relationships to disclose
• 

  Adnan Kastrati, MD

  Senior Consultant, Head of Catheterization Laboratory
  Deutsches Herzzentrum Muenchen
  Munich, Bayern, Germany

  Disclosure(s): No financial relationships to disclose

Panel Discussant(s)

• 

  Tiziana Claudia Aranzulla, MD, MSc

  Interventional cardiology
  A.O. Ordine Mauriziano di Torino
  Turin, Italy

  Disclosure(s): No financial relationships to disclose
• 

  Abhishek Chaturvedi, MD

  Interventional Cardiologist & Assistant Professor of Medicine
  West Virginia University Heart & Vascular Institute, United States

  Disclosure(s): No financial relationships to disclose
• 

  Michael J. Cowley, MD, MSCAI

  Emeritus Professor of Medicine (Cardiology)
  Virginia Commonwealth University Medical Center, Pauley Heart Center
  Cary, North Carolina, United States

  Disclosure(s): No financial relationships to disclose
• 

  Joost Daemen, MD, PhD

  Interventional Cardiologist
  Erasmus MC Thoraxcenter
  Rotterdam, Zuid-Holland, Netherlands

  Disclosure information not submitted.
• 

  Stephen G. Ellis, MD, FACC, FSCAI

  Director of Interventional Cardiology, Senior Academic Officer
  Cleveland Clinic
  Beachwood, Ohio, United States

  Disclosure(s): No financial relationships to disclose
• 

  Patrick W. Serruys, MD, PhD

  Professor of Medical Intervention & Innovation
  University of Galway, Ireland

  Disclosure information not submitted.
• 

  Christian Spaulding, MD, PhD

  Professor of Cardiology
  European Hospital Georges Pompidou, Paris, France
  Paris, France

  Disclosure(s): Abbott, Asahi, BD, Boston Scientific, Conavi, Cook, Cordis, Endovascular Engineering, Evident Vascular, Gore, InfraRedx, Medtronic, Penumbra, Philips, RapidAI, Rampart IC, R3, Regeneron, Shockwave, Siemens, SoniVie, Teleflex, Terumo, Thrombolex, Vent: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Boston Scietific: Consulting Fees (e.g., advisory boards) (Terminated, September 30, 2025); CERC: Grant/Research Support (Ongoing); Cordis, Endovascular Division: Consulting Fees (e.g., advisory boards) (Ongoing); Daiichi Sankyo, Boeringer Ingelheim , Sanofi, AstraZeneca , Chiesi, Bracco, Amgen, Novo Nordisk, Philips: Consulting Fees (e.g., advisory boards) (Terminated, June 30, 2025); French Ministry of Health: Grant/Research Support (Terminated, January 2, 2025); MedAlliance: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Medtronic, Novartis, OrbusNeich, Penumbra, PhaseBio, Philips, Pi-Cardia, PLx Pharma, Protembis, RenalPro, RM Global, Shockwave, Vivasure, Zoll: Consulting Fees (e.g., advisory boards) (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Terminated, July 30, 2025); Techwald: Consulting Fees (e.g., advisory boards) (Ongoing), Stock Options [in privately held companies] (Ongoing); Valcare Medical: Consulting Fees (e.g., advisory boards) (Terminated, September 30, 2025)
• 

  Olga Toleva, MD, MPH

  Lead of Advanced Coronary Physiology Program
  Georgia Heart Institute
  Gainesville, Georgia, United States

  Disclosure information not submitted.